Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERO-UTUC: Disitamab Vedotin to Prevent Bladder Recurrence in HER2-Positive UTUC
NCT07591805Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in upper tract urothelial carcinoma (UTUC), sponsored by Renji Hospital. Primary endpoint: 12-Month Intravesical Recurrence Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07591805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591805.